Preclinical efficacy and safety of AAVrh10-based plakophilin-2 gene therapy (LX2020) as a treatment for arrhythmogenic cardiomyopathyAAVrh10介导的桥粒蛋白-2基因疗法(LX2020)治疗致心律失常性心肌病的临床前有效性与安全性研究NPJ REGENERATIVE MEDICINEIF6.52025-04-030OAAI
Preclinical Evidence of Long-term Efficacy and Safety of LX2020, an AAV based Plakophilin-2 Gene Therapy, for the Treatment of Arrhythmogenic CardiomyopathyCIRCULATION RESEARCHIF16.22024-08-020PRE
PR001 gene therapy increased GCase activity and improved neuronopathic Gaucher disease phenotypesMOLECULAR GENETICS AND METABOLISMIF3.52021-02-010PREAI
Gene therapy PR006 increased progranulin levels and improved lysosomal related phenotypes in model systemsMOLECULAR GENETICS AND METABOLISMIF3.52020-02-010PREAI
Gene therapy PR001 increased GCase activity and improved neuronopathic Gaucher disease phenotypes in mouse modelsMOLECULAR GENETICS AND METABOLISMIF3.52020-02-010PREAI
Homozygosity at chromosome 8qter in individuals affected by mal de Meleda (Meleda disease) originating from the island of MeledaBRITISH JOURNAL OF DERMATOLOGYIF9.62001-04-0113PREAI